OncoMatch/Clinical Trials/NCT06498479
ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
Is NCT06498479 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including HS-20093 and Topotecan for small cell lung cancer.
Treatment: HS-20093 · Topotecan — The main objective of this study is to compare the efficacy of HS-20093 with standard of care (SOC) on prolonging overall survival (OS) in subjects with relapsed small cell lung cancer (SCLC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — first-line
Subjects who progressed on or after first-line platinum-based regimens.
Cannot have received: B7-H3 targeted agent
Has received prior treatment with anti-B7 homologue 3 (B7-H3) targeted agents.
Cannot have received: topoisomerase I inhibitor
Has received prior treatment with topoisomerase I inhibitor, including ADC that consists of topoisomerase I inhibitor.
Lab requirements
Blood counts
Inadequate bone marrow reserve [excluded]
Kidney function
Hepatorenal syndrome [excluded]
Liver function
Current hepatic encephalopathy, hepatorenal syndrome, or Child-Pugh Grade B or more severe cirrhosis [excluded]
Cardiac function
Evidence of cardiovascular risks; severe, uncontrolled or active cardiovascular diseases [excluded]
Inadequate bone marrow reserve or organ dysfunction. Evidence of cardiovascular risks. Severe, uncontrolled or active cardiovascular diseases. Current hepatic encephalopathy, hepatorenal syndrome, or Child-Pugh Grade B or more severe cirrhosis.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify